Country: United States
Language: English
Source: NLM (National Library of Medicine)
LAMOTRIGINE (UNII: U3H27498KS) (LAMOTRIGINE - UNII:U3H27498KS)
JUBILANT CADISTA PHARMACEUTICALS INC.
LAMOTRIGINE
LAMOTRIGINE 25 mg
ORAL
PRESCRIPTION DRUG
Adjunctive Therapy Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: - partial-onset seizures. - primary generalized tonic-clonic (PGTC) seizures. - generalized seizures of Lennox-Gastaut syndrome. Monotherapy Lamotrigine tablets are indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. Lamotrigine tablets are indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixe
Lamotrigine Tablets USP, 25 mg Round, white to off-white tablets, debossed with ‘J 245’ on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-245-01 Bottles of 500 tablets with Plain Closure, NDC 59746-245-05 Bottles of 1000 tablets with Plain Closure, NDC 59746-245-10 Lamotrigine Tablets USP, 100 mg Round, white to off-white tablets, debossed with ‘J 246’ on one side and scored on the other side. Bottles of 100 tablets with Child Resistant Closure, NDC 59746-246-01 Bottles of 1000 tablets with Plain Closure, NDC 59746-246-10 Lamotrigine Tablets USP, 150 mg Round, white to off-white tablets, debossed with ‘J 247’ on one side and scored on the other side. Bottles of 60 tablets with Child Resistant Closure, NDC 59746-247-60 Bottles of 500 tablets with Plain Closure, NDC 59746-247-05 Lamotrigine Tablets USP, 200 mg Round, white to off-white tablets, debossed with ‘J 248’ on one side and scored on the other side. Bottles of 60 tablets with Child Resistant Closure, NDC 59746-248-60 Bottles of 500 tablets with Plain Closure, NDC 59746-248-05 Store at 20o C to 25o C (68o F to 77o F); excursions permitted to 15o C to 30o C (59o F to 86°F) [see USP Controlled Room Temperature] in a dry place and protect from light.
Abbreviated New Drug Application
LAMOTRIGINE - lamotrigine tablet LAMOTRIGINE- lamotrigine tablet JUBILANT CADISTA PHARMACEUTICALS INC. ---------- MEDICATION GUIDE Lamotrigine tablets, USP (la-MOE-tri-jeen) What is the most important information I should know about Lamotrigine tablets? 1. Lamotrigine tablets may cause a serious skin rash that may cause you to be hospitalized or even cause death. There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with Lamotrigine tablets, but is more likely to happen within the first 2 to 8 weeks of treatment. Children and teenagers aged between 2 and 17 years have a higher chance of getting this serious skin rash while taking Lamotrigine tablets. The risk of getting a serious skin rash is higher if you: • take Lamotrigine tablets while taking valproate [*DEPAKENE (valproic acid) or *DEPAKOTE (divalproex sodium)]. • take a higher starting dose of Lamotrigine tablets than your healthcare provider prescribed. • increase your dose of Lamotrigine tablets faster than prescribed. Call your healthcare provider right away if you have any of the following: • a skin rash • blistering or peeling of your skin • hives • painful sores in your mouth or around your eyes These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking Lamotrigine tablets. 2. Other serious reactions, including serious blood problems or liver problems. Lamotrigine tablets can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of these symptoms: • fever • frequent infections • severe muscle pain • swelling of your face, eyes, lips, or tongue • swollen lymph glands • unusual bruising or bleeding, looking pale • weakness, fatigue • yellowing of your s Read the complete document
LAMOTRIGINE - LAMOTRIGINE TABLET LAMOTRIGINE- LAMOTRIGINE TABLET JUBILANT CADISTA PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LAMOTRIGINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LAMOTRIGINE TABLETS. LAMOTRIGINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1994 WARNING: SERIOUS SKIN RASHES _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CASES OF LIFE-THREATENING SERIOUS RASHES, INCLUDING STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS, AND/OR RASH-RELATED DEATH HAVE BEEN CAUSED BY LAMOTRIGINE. THE RATE OF SERIOUS RASH IS GREATER IN PEDIATRIC PATIENTS THAN IN ADULTS. ADDITIONAL FACTORS THAT MAY INCREASE THE RISK OF RASH INCLUDE: COADMINISTRATION WITH VALPROATE. EXCEEDING RECOMMENDED INITIAL DOSE OF LAMOTRIGINE. EXCEEDING RECOMMENDED DOSE ESCALATION FOR LAMOTRIGINE. (5.1) BENIGN RASHES ARE ALSO CAUSED BY LAMOTRIGINE; HOWEVER, IT IS NOT POSSIBLE TO PREDICT WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE-THREATENING. LAMOTRIGINE SHOULD BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. (5.1) RECENT MAJOR CHANGES Warnings and Precautions, Cardiac Rhythm and Conduction Abnormalities (5.4) 03/2021 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. (1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) Limitations of Use: Treatment of acute manic or mixed episodes is not reco Read the complete document